Document Detail


Intrathecal baclofen therapy over 10 years.
MedLine Citation:
PMID:  15673207     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Intrathecal baclofen (ITB) therapy has evolved into a standard treatment for severe spasticity. After this therapy had been provided for 10 years, a retrospective chart review on 50 patients, representing a total 2,922 patient months of ITB service, was done. These patients suffered severe spasticity from a number of disease processes including multiple sclerosis, cerebral palsy, and brain injury. The average dosage for the total group was 463 micrograms per day (microg/day), and 32% used a simple infusion mode. Pump refills occurred every 3 months for 58% of the group. Three evolving trends in ITB therapy were identified from clinical trial to current management: (a) higher catheter tip placement, (b) use of more complex infusion modes, and (c) a decreased complication rate.
Authors:
Patrice Korth Rawlins
Related Documents :
15336867 - Diagnosis and treatment of candida vertebral osteomyelitis: clinical experience with a ...
3826097 - Indwelling urinary catheters in the elderly. relation of "catheter life" to formation o...
1484757 - Atypical thrombotic and septic complications of totally implantable venous access devic...
10947017 - A prospective analysis of the cephalic vein cutdown approach for chronic indwelling cen...
7244907 - Aortic valve replacement in the elderly.
21184987 - Identifying patients at risk for premature discontinuation of thienopyridine after coro...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses     Volume:  36     ISSN:  0888-0395     ISO Abbreviation:  J Neurosci Nurs     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2005-01-27     Completed Date:  2005-02-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8603596     Medline TA:  J Neurosci Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  322-7     Citation Subset:  IM; N    
Affiliation:
Neuroscience Implant Program at Via Christi Regional Medical Center, Wichita, KS, USA. patrice_rawlins@via-christi.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Baclofen / administration & dosage*,  adverse effects
Brain Injuries / drug therapy
Cerebral Palsy / drug therapy
Child
Child, Preschool
Drug Implants
Humans
Infant
Injections, Spinal
Middle Aged
Multiple Sclerosis / drug therapy
Muscle Relaxants, Central / administration & dosage*,  adverse effects
Muscle Spasticity / drug therapy*
Patient Satisfaction
Retrospective Studies
Chemical
Reg. No./Substance:
0/Drug Implants; 0/Muscle Relaxants, Central; 1134-47-0/Baclofen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The influence of resources on perceived functional limitations among women with multiple sclerosis.
Next Document:  West Nile virus--the eye of the storm: a case study.